Immediately before use, the coated wells were overlaid with 1% bo

Immediately before use, the coated wells were overlaid with 1% bovine serum albumin (BSA) for 30 min, washed 5 times with PBS, and dried for 30 min at room temperature in the tissue culture hood. selleck products Adjusted viable cells concentration was counted with trypan blue exclusion. The cells were loaded into individual wells (1 × 104 cells/well) and incubated for 30 min at 37°C in a 5% CO2 atmosphere. Nonadherent cells were aspirated and washed 3 times. Adherent cells were counted under an Olympus microscope (Olympus, Tokyo, Japan) at 20× magnification. The measurements were conducted in triplicate for each experimental group. Statistical analysis All

the results were expressed as the mean ± SD of several independent experiment values. Multiple comparisons of the data were performed by analysis of selleck variance (ANOVA) with Dunnett’s test. P values < 1% were regarded as significant. Results Cytotoxicity toward B16BL6 cells Cell viability of B16BL6 cells was assessed in the presence of fluvastatin (range, 0.01-0.5 μM) or simvastatin

(range, 0.1-5 μM) in order to examine the cytotoxic effects of fluvastatin or simvastatin. We determined the cell survival rate, which was defined as the number of living cells as compared with the number of live control cells (0.1% DMSO-treated). The cell survival rates were calculated 1, 3, and 5 d after fluvastatin or simvastatin exposure. In the presence of 0.01, 0.05, 0.1, and 0.5 μM fluvastatin, the cell survival rates were 99.39%, 94.74%, 81.59%, and 50.77%, respectively, on day 5 (Figure 1A). In the presence of 0.1, 0.5, 1, and 5 μM simvastatin, the cell survival rates were 105.80%, 89.16%, selleck screening library 84.84%, and 75.52%, respectively, on day 5 (Figure 1B). A decrease in the number of B16BL6 cells was observed at day 5 after

the administration of 0.1 and 0.5 μM fluvastatin or 0.5, 1, and 5 μM simvastatin (P < 0.01). On the basis of these results, we selected 0.05 μM and 0.1 μM as the concentrations at which fluvastatin and simvastatin, respectively, were not cytotoxic toward B16BL6 cells. Figure 1 Inhibitory effect of statins on tumor cell metastasis, migration, and invasion. (A, B) Determination of the statin concentrations suitable for administration to B16BL6 cells. The cells were incubated Orotidine 5′-phosphate decarboxylase in 96-well plates for 24 h and then treated with 0.01-0.5 μM fluvastatin, or 0.1-5 μM simvastatin. After 1, 3, or 5 d, cell viability was quantified by WST-8 assays. The results are representative of 5 independent experiments. (C) B16BL6 cells, which had been pretreated with 0.05 μM fluvastatin or 0.1 μM simvastatin for 3 d, were injected into the tail veins of syngeneic C57BL/6J mice. After 14 d, visible nodules that had metastasized to the lungs were counted. The results are expressed as the mean ± SD of 9 mice. (D, E) B16BL6 cells were pretreated with 0.05 μM fluvastatin or 0.1 μM simvastatin for 3 d, after which cells were seeded into the upper compartments of chambers.

Comments are closed.